The Bundibugyo strain of the Ebola virus has been devastating the Democratic Republic of the Congo, with no vaccine currently approved to protect against the strain.

The trial could begin within two weeks if it receives regulatory and ethical approval, the Addis Ababa-based agency said in an email Sunday.

The Bundibugyo strain of the Ebola virus has been devastating the Democratic Republic of the Congo, with no vaccine currently approved to protect against the strain.